
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+38
Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors)....
Biotechnology,immunotherapy,cell therapy,gene therapy,regenerative medicine,t-cells,cytotoxic t lymphocytes,ctls,allogeneic,off the shelf,cancer,oncology,immuno-oncology,hematology,immunology,autoimmune diseases,multiple sclerosis,ms,epstein-barr virus,ebv,post-transplant lymphoproliferative disorder,ptld,nasopharyngeal carcinoma,cytomegalovirus,cmv,oncoviruses,bone marrow transplant,stem cell transplant,solid organ transplant,lymphoma,secondary lymphoma,secondary malignancy,lymphoproliferative disorders,ebv lymphoma,atara bio,atara,atra,car t,solid tumors,allogeneic cd19 car t,allogeneic ebv car t-cell platform,allogeneic car t-cell therapies,and progressive multiple sclerosis
Atara biotherapeutics operates in the Biotechnology research industry.
Atara biotherapeutics's revenue is 101m - 500m
Atara biotherapeutics has 201 - 500 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.